Adam D. Cohen

Hospital of the University of Pennsylvania — United States

Medicine · Health Sciences

63h-index18.1kcitations437works10.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(215), CAR-T cell therapy research(163), Immunotherapy and Immune Responses(74), Protein Degradation and Inhibitors(54), Monoclonal and Polyclonal Antibodies Research(50)

Publications436 total

Outcomes of radiation integrated with T-cell–engaging bispecific antibodies in relapsed/refractory multiple myeloma
Blood Advances·2025· 1 citedOpen Access
Supplementary Tables and Figures from Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
2025Open Access
Outcomes of relapse after teclistamab therapy in multiple myeloma
Blood Cancer Journal·2025Open Access
Chimeric antigen receptor T-cell therapy in patients with coexisting malignancy and autoimmune disease
Blood·2025Open Access
Rebuilding immunity: Kinetics and clinical impact of immune reconstitution after CAR T-cell therapy in multiple myeloma
Blood·2025Open Access
CCR5 blockade: A therapeutic approach to uncouple CART-BCMA expansion from CART-mediated immune toxicities.
Blood·2025Open Access
TIP-14. Trial in Progress (TiP): Interim analysis of a Phase 2 study of BPM31510 (a lipid nanodispersion of oxidized CoQ10) with Vitamin K in combination with Standard of Care (SOC) RT and TMZ in Glioblastoma Multiforme (GBM) patients without prior therapy
Neuro-Oncology·2025Open Access
REMISSÃO E SOBREVIDA DE LONGO PRAZO (≥5 ANOS) APÓS TRATAMENTO COM CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) EM PACIENTES DO CARTITUDE-1 COM MIELOMA MÚLTIPLO RECIDIVADO/REFRATÁRIO (RRMM)
Hematology Transfusion and Cell Therapy·2025Open Access
Outcomes of Radiation Therapy Integrated with T-cell Engaging Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025
Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy: Preliminary Safety and Efficacy Data from the “STEM” (Sequential T Cell-Engagement for Myeloma) Trial
Clinical Lymphoma Myeloma & Leukemia·2025
722eTiP Interim analysis of a phase II study of BPM31510 (a lipid nanodispersion of oxidized CoQ10) with vitamin K in combination with Standard of care (SOC) RT and TMZ in glioblastoma multiforme (GBM) patients without prior therapy
Annals of Oncology·2025
Absolute Lymphocyte Count as a Key Biomarker for Monitoring Safety After Ciltacabtagene Autoleucel
Clinical Lymphoma Myeloma & Leukemia·2025
CD4+ T-Cells Mediate Immune-Related Adverse Events (CirAE) Following BCMA CAR-T Therapy
Clinical Lymphoma Myeloma & Leukemia·2025
MM-1081: Absolute Lymphocyte Count as a Key Biomarker for Monitoring Safety After Ciltacabtagene Autoleucel
Clinical Lymphoma Myeloma & Leukemia·2025
Belantamab mafodotin does not induce B-cell maturation antigen loss or systemic immune dysfunction in multiple myeloma
Haematologica·2025· 1 citedOpen Access
POSTER: MM-1081 Absolute Lymphocyte Count as a Key Biomarker for Monitoring Safety After Ciltacabtagene Autoleucel
Clinical Lymphoma Myeloma & Leukemia·2025
Access and outcomes of racial and ethnic minority populations receiving commercial anti-BCMA CART for myeloma
Blood Immunology & Cellular Therapy·2025· 3 citedOpen Access
Point-of-Care Ultrasound in Pediatric Hospital Medicine: A National Survey
Hospital Pediatrics·2025· 3 cited
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology·2025· 40 citedOpen Access
Clinical activity of novel targeting of S100A9 with tasquinimod for relapsed and refractory multiple myeloma (RRMM).
Journal of Clinical Oncology·2025
page 1 of 22Next →

Frequent Co-authors

Edward A. Stadtmauer(12), Dan T. Vogl(10), Alfred L. Garfall(9), Alexander M. Lesokhin(8), Nikhil C. Munshi(7), Sundar Jagannath(7), Carl H. June(7), Brendan M. Weiss(7), Jesús G. Berdeja(6), Saad Z. Usmani(6), Enrique Zudaire(6), J. Joseph Melenhorst(6), Bruce L. Levine(6), Wei‐Ting Hwang(6), Deepu Madduri(5), Andrzej Jakubowiak(5), Mounzer Agha(5), Parameswaran Hari(5), Elizabeth O’Donnell(5), David Avigan(5)